For Clinicians

EAA™ Dose Response

 

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc. at info@spectraldx.com to obtain appropriate product information for your country.

The EAA™ dose response is an exponential curve, characterized by two asymptotes. The two asymptote regions are the high and low non measurable regions of the curve. Recent data suggests that PMX works best on patients with EAA results of ≥0.60 and <0.90. The efficacy of the product has not been demonstrated for patients with EAA levels ≥0.9. Care should be taken when interpreting EAA results greater than 0.9 as small differences in EAA values correlate to large differences in endotoxin concentration due to the asymptote at EAA value 1.0.

 

 

 

 

Spectral Medical Inc. © 2014-2018

135 The West Mall, Unit 2 •  Toronto, Ontario  •  M9C 1C2  Canada

Tel: 1.416.626.3233  •  Toll Free: 1.888.426.4264  •  Fax: 1.416.626.7383

info@spectraldx.com